Shattuck Labs
STTK
5.44
-0.22
-3.80%
Shattuck Labs
US · STTK
#3662 by market cap
Listed 2020
5.44
-0.22
-3.80%
Live - 5344 symbols - heartbeat 376s ago
· 2026-10-08 09:58
Pre-market
5.65
-0.09%
After-hours
5.66
0.00%
Overnight
5.57
-1.50%
- Market cap
- 545.98M
- P/E (TTM)i
- -12.36
- P/Bi
- 2.59
- EPSi
- -0.70
- Div yieldi
- 0.00%
- 52W posi
- 56%
Reader sentiment
Are you bullish or bearish on STTK?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.5 percentage points.
Institutional ownership
- Held by institutions
- 81.90% -1.54pp
- Institutions
- 124 +2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund36.90%
Hedge Fund28.61%
VC/PE Fund13.71%
Individual/Insider6.96%
Family Office/Trust1.60%
Public Company0.74%
Private Company0.20%
Other11.16%
Top holders as of 2026-06-30
T. Rowe Price Group, Inc.
16.02% · 16.07M sh
Adage Capital Management, L.P.
8.09% · 8.12M sh
OrbiMed Advisors LLC
6.28% · 6.31M sh
Prosight Management, LP
5.94% · 5.96M sh
Redmile Group, LLC
5.21% · 5.23M sh
BlackRock
3.92% · 3.94M sh
Frazier Life Sciences Management, LP
3.74% · 3.75M sh
Nextbio Capital Management LP
3.71% · 3.73M sh
Deep Track Capital, LP
3.69% · 3.71M sh
Vanguard Capital Management, LLC
3.66% · 3.67M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 34 buys · 16 sells
| Name | Role | Stake |
|---|---|---|
| Josiah Hornblower | Co-Founder & Former Chairman of the Board | 2.97% |
| Taylor Schreiber | Chief Executive Officer | 2.72% |
| Clay Siegall | Director | 0.32% |
| Andrew Neill | Chief Financial Officer | 0.29% |
| Tyler Brous | Lead Independent Director | 0.24% |
| Arunthathy Pandite | Chief Medical Officer | 0.14% |
| Abhinav Shukla | Chief Technology Officer | 0.08% |
| Stephen Stout | General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer | 0.06% |
| George Golumbeski | Independent Chairperson | 0.05% |
| Neil W. Gibson | Independent Director | 0.05% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-05 | Abhinav Shukla | Chief Technology Officer | Derivative Exercise and Retained | +12,153 | $3.57 |
| 2026-07-01 | Abhinav Shukla | Chief Technology Officer | Derivative Exercise and Sale | -410 | $3.57–7.01 |
| 2026-06-30 | Abhinav Shukla | Chief Technology Officer | Derivative Exercise and Sale | -23,465 | $3.57–7.08 |
| 2026-06-30 | Abhinav Shukla | Chief Technology Officer | Intent to Sell (Form 144) | -100 | $7.07 |
| 2026-06-29 | Arunthathy Pandite | Chief Medical Officer | Automatic Disposition | -30,000 | $7.01 |
| 2026-06-29 | Abhinav Shukla | Chief Technology Officer | Intent to Sell (Form 144) | -23,365 | $7.08 |
| 2026-06-10 | OrbiMed Advisors LLC | -- | Open Market Derivative Acquisiti | +1,250,000 | $0.00 |
| 2026-06-08 | Clay Siegall | Director | Open Market Acquisition | +62,500 | $4.00 |
| 2026-06-07 | OrbiMed Advisors LLC | -- | Other Derivative Acquisition | +18,439,788 | $0.00 |
| 2026-06-07 | Mona Ashiya | Director | Other Derivative Acquisition | +18,439,788 | $0.00 |
| 2026-05-28 | Clay Siegall | Director | Other Derivative Acquisition | +81,000 | $5.95 |
| 2026-05-28 | Neil W. Gibson | Independent Director | Other Derivative Acquisition | +81,000 | $5.95 |
| 2026-05-28 | Mona Ashiya | Director | Other Derivative Acquisition | +81,000 | $5.95 |
| 2026-05-28 | George Golumbeski | Independent Chairperson | Other Derivative Acquisition | +81,000 | $5.95 |
| 2026-05-28 | Helen Boudreau | Independent Director | Other Derivative Acquisition | +81,000 | $5.95 |
| 2026-05-28 | Daniel Baker | Director | Other Derivative Acquisition | +81,000 | $5.95 |
| 2026-05-21 | Clay Siegall | Director | Derivative Exercise and Retained | +128,054 | $1.08 |
| 2026-05-20 | Abhinav Shukla | Chief Technology Officer | Derivative Exercise and Retained | +5,122 | $1.08 |
| 2026-05-14 | Stephen Stout | General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer | Other Acquisition | +12,805 | $1.08 |
| 2026-05-11 | Taylor Schreiber | Chief Executive Officer | Derivative Exercise and Retained | +25,610 | $1.08 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:58:42 · For reference only, not investment advice and not tailored to your situation.